Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BRIDGEWATER, N.J., June 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 103 new employees.

PRNewsWire • Jun 4, 2026

Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference

BRIDGEWATER, N.J., May 27, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the 2026 Goldman Sachs Annual Global Healthcare Conference in Miami on Tuesday, June 9, 2026, at 10:00 a.m.

PRNewsWire • May 27, 2026

Insmed Incorporated (INSM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Insmed Incorporated (INSM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 20, 2026

Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus

Insmed NASDAQ: INSM Chair and CEO Will Lewis said the company remains confident in the launch trajectory of BRINSUPRI, despite investor concerns over discontinuation rates that followed the company's latest update. Speaking at a Bank of America healthcare conference, Lewis said the company intended to provide “anchor points” around what he described as “one of the strongest launches in recent years.

MarketBeat • May 18, 2026

Insmed Incorporated (INSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Insmed Incorporated (INSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 12, 2026

Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%

INSM stock plunges 23% after Q1 sales miss estimates despite 230% revenue growth and strong Brinsupri uptake.

Zacks Investment Research • May 8, 2026

Insmed Tanks On Its Most Important Launch; Why Analysts Remain Bullish

Insmed stock tanked Thursday after its new lung drug, Brinsupri, missed elevated buy-side expectations, though beat sell-side views.

Investors Business Daily • May 7, 2026

Insmed Incorporated (INSM) Q1 2026 Earnings Call Transcript

Insmed Incorporated (INSM) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 7, 2026

Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update

— Total Company Revenues of $306.0 Million for the First Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $207.9 Million for the First Quarter of 2026, Reflecting 44% Growth Over the Fourth Quarter of 2025— — ARIKAYCE ® (amikacin liposome inhalation suspension) Revenues of $98.1 Million for the First Quarter of 2026, Reflecting 6% Growth Over the First Quarter of 2025— —Company Reiterates 2026 BRINSUPRI Revenue Guidance of at Least $1 Billion and 2026 ARIKAYCE Revenue Guidance of $450 Million to $470 Million— — Phase 3b ENCORE Study of ARIKAYCE in Patients with MAC Lung Disease Met Primary and All Multiplicity-Controlled Secondary Culture Conversion Endpoints— —Phase 3 PALM-PAH Study of TPIP in Patients with PAH Initiated in April 2026— BRIDGEWATER, N.J., May 7, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

PRNewsWire • May 7, 2026

Insmed (INSM) Reports Q1 Loss, Misses Revenue Estimates

Insmed (INSM) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.9. This compares to a loss of $1.42 per share a year ago.

Zacks Investment Research • May 7, 2026